contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


newbury-pharmaceuticals-secures-approval-for-macitentan-film-coated-tablets

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Newbury Pharmaceuticals is a pharmaceutical company. The company develops a pipeline of in-house developed and licensed products with a focus on specialty drugs in areas such as oncology, rare diseases, and neurology. The company conducts its business within the Scandinavian market. Newbury Pharmaceuticals was founded in 2020 and has its headquarters in Lund.

Newbury Pharmaceuticals

Newbury Pharmaceuticals is pleased to announce the successful Marketing Authorization (MA) of Macitentan Newbury in Denmark as the first country in a Scandinavian registration procedure. Approvals...

<div class="mfn-preamble"><p><strong>Newbury Pharmaceuticals is pleased to announce the successful Marketing Authorization (MA) of Macitentan Newbury in Denmark as the first country in a Scandinavian registration procedure. Approvals in Sweden and Norway are expected to follow upon the completion of national reviews.</strong></p></div><div class="mfn-body"><p>Macitentan is a medicine used for the long-term treatment of pulmonary arterial hypertension (PAH), a condition in which there is abnormally high blood pressure in the arteries of the lungs, causing symptoms such as breathlessness and fatigue.<br>&nbsp;<br>Macitentan is used for adults, adolescents and children aged less than 18 years and bodyweight ≥ 40 kg in whom PAH comes with moderate or marked limitations in physical activity (corresponding to WHO functional class II or III, respectively). Macitentan can be used alone or in combination with other PAH medicines.<br>&nbsp;<br>Macitentan Newbury is a generic version of Opsumit®. The current annual value of the Scandinavian market is estimated to be 15 MEUR according to DLMI Nordic Pharma Insights.</p><blockquote><em>“This rare disease medicine further strengthens the ambition to have a positive impact in society with products and technologies that contribute to the overall health care system and patient well-being. Based on this positive progress, we will proceed to launch this product within respective markets as soon as regulatory exclusivities and patents allow us.” says Mr. Lars Minor, CEO of Newbury. </em></blockquote></div><div class="mfn-footer mfn-contacts mfn-e2b1977b3686"><p><strong class="mfn-heading-1">For more information, contact:</strong></p><hr><p>Lars Minor, CEO<br><a rel="noopener" href="mailto:lars.minor@newburypharma.com">lars.minor@newburypharma.com</a><br>Mobile: +46 72-377 3005</p><p><a rel="noopener" href="http://www.newburypharma.com/">www.newburypharma.com</a></p></div><div class="mfn-footer mfn-about mfn-488d133b85e8"><p><strong class="mfn-heading-1">About Newbury Pharmaceuticals</strong></p><hr><p>Newbury Pharmaceuticals is building a pipeline of proprietary and licensed products with focus on specialty and branded products in the Nordics. Newbury aims to make a difference by offering treatment solutions within areas like oncology, rare diseases and neurology. The portfolio is built by leveraging experience and extensive international network. Newbury offers strategic partnerships of innovation for the benefit of the Nordic healthcare market.</p><p>Västra Hamnen Corporate Finance is the Company's Certified Adviser on Nasdaq First North and can be reached at ca@vhcorp.se or +46 (0) 40 200 250.</p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong></p><hr><p><a rel="noopener" href="https://storage.mfn.se/462571ee-4e24-4b78-8e9f-584b6d7d84e5/newbury-pharmaceuticals-secures-approval-for-macitentan-film-coated-tablets.pdf" class="mfn-generated mfn-primary">Newbury Pharmaceuticals Secures Approval for Macitentan film-coated tablets</a></p></div>